CARE Trial
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
CARE Trial On the Web |
|
American Roentgen Ray Society Images of CARE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for CARE Trial.
Objective
To assess if pravastatin would reduce the sum of fatal coronary artery disease (CAD) and nonfatal myocardial infarction (MI) in patients who had a previous MI and a total cholesterol value < 240 mg/dl.
Methods
Cholesterol and Recurrent Events trial was a double blinded, randomized study wherein 4159 patients with a history of a myocardial infarction in the previous two years who had a total cholesterol value < 240 mg/dl were enrolled and treated with either 40 mg pravastatin or a placebo.
Results
The following results were obtained after a median follow-up time of 5 years:
- Reduced combined end point of coronary death and nonfatal MI (10.2 versus 13.2 percent)
- Reduced need for revascularization with CABG or PTCA (14.1 versus 18.8 percent)
- Reduced frequency of stroke (2.6 versus 3.8 percent) and of stroke plus transient ischemic attacks (4.4 versus 6.0 percent)[1][2]
References
- ↑ Sacks FM, Pfeffer MA, Moye LA; et al. (1996). "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators". The New England Journal of Medicine. 335 (14): 1001–9. doi:10.1056/NEJM199610033351401. PMID 8801446. Unknown parameter
|month=ignored (help) - ↑ Pfeffer MA, Sacks FM, Moyé LA; et al. (1995). "Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators". The American Journal of Cardiology. 76 (9): 98C–106C. PMID 7572695. Unknown parameter
|month=ignored (help)